VRDN - CIK 0001590750
The table below shows Viridian Therapeutics, Inc.DE's balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets | $784.74M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $571.91M |
| $578.75M |
| $657.24M |
| $767.36M |
| $581.66M |
| Property, plant & equipment | $1.13M | $1.13M | $1.09M | $1.16M | $1.29M | $1.51M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $789.02M | $577.14M | $582.32M | $660.98M | $771.90M | $585.66M |
| Accounts payable | $13.31M | $10.06M | $8.52M | $3.89M | $6.34M | $3.14M |
| Total current liabilities | $51.80M | $50.70M | $52.59M | $33.73M | $41.36M | $36.76M |
| Long-term debt | - | $20.89M | $12.35M | $20.68M | $20.52M | $17.49M |
| Total liabilities | $153.01M | $74.17M | $67.16M | $56.51M | $64.40M | $56.33M |
| Retained earnings | -$1.44B | -$1.22B | -$1.18B | -$1.08B | -$916.13M | -$839.44M |
| Total equity | $636.01M | $502.97M | $515.17M | $604.47M | $707.50M | $529.34M |